Table 1. Meta-analysis of 1q22 and 19p12 loci for genetic association with survival outcomes in ovarian cancer patients.
| Variant | Position (hg19) | OS any chemotherapy (n=6,160) | OS standard chemotherapy (n=2,620) | PFS any chemotherapy (n=5,596) | PFS standard chemotherapy (n=2,352) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Effect allele/Ref allele | EAF§ | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | ||
| 1q22 region | |||||||||||
| rs6674079* | 156486061 | A/G | 0.60 | 0.93 (0.88-0.98) | 0.010 | 0.95 (0.88-1.04) | 0.257 | 0.98 (0.93-1.03) | 0.398 | 1.00 (0.93-1.08) | 0.918 |
| rs11264494¶ | 156493398 | C/T | 0.51 | 0.91 (0.86-0.96) | 2.6×10-4 | 0.91 (0.84-0.99) | 0.023 | 0.92 (0.88-0.97) | 0.001 | 0.92 (0.86-0.99) | 0.024 |
| rs2274500¶ | 156850112 | G/T | 0.86 | 1.09 (0.98-1.21) | 0.110 | 1.24 (1.06-1.45) | 0.007 | 1.05 (0.95-1.16) | 0.312 | 1.16 (1.00-1.35) | 0.047 |
| rs60989774¶ | 156513579 | CT/C | 0.38 | 1.08 (1.02-1.14) | 0.006 | 1.08 (1.00-1.18) | 0.061 | 1.11 (1.05-1.17) | 8.0×10-4 | 1.11 (1.02-1.20) | 0.011 |
| rs59359496¶ | 156501450 | T/G | 0.08 | 1.04 (0.95-1.14) | 0.422 | 1.07 (0.93-1.23) | 0.340 | 1.13 (1.03-1.23) | 0.007 | 1.21 (1.07-1.38) | 0.003 |
| rs947661# | 156494916 | A/G | 0.36 | 1.10 (1.04-1.16) | 8.2×10-4 | 1.09 (1.00-1.19) | 0.050 | 1.04 (0.99-1.10) | 0.118 | 1.04 (0.96-1.12) | 0.367 |
| rs10159180# | 156480324 | C/T | 0.46 | 0.92 (0.87-0.97) | 0.001 | 0.93 (0.86-1.01) | 0.089 | 0.94 (0.89-0.98) | 0.007 | 0.95 (0.88-1.02) | 0.176 |
| rs942964# | 156481707 | A/G | 0.54 | 1.09 (1.03-1.15) | 0.001 | 1.07 (0.99-1.16) | 0.097 | 1.07 (1.02-1.12) | 0.010 | 1.05 (0.98-1.13) | 0.178 |
| rs11264488# | 156480288 | C/G | 0.56 | 1.08 (1.03-1.14) | 0.004 | 1.05 (0.97-1.14) | 0.194 | 1.07 (1.02-1.13) | 0.005 | 1.05 (0.98-1.13) | 0.171 |
| rs11264489# | 156480831 | A/G | 0.60 | 0.92 (0.87-0.97) | 0.004 | 0.95 (0.87-1.03) | 0.194 | 0.98 (0.93-1.03) | 0.365 | 1.00 (0.93-1.08) | 0.990 |
| rs7550381# | 156495001 | A/G | 0.60 | 0.92 (0.87-0.97) | 0.004 | 0.94 (0.87-1.03) | 0.181 | 0.96 (0.92-1.01) | 0.156 | 0.98 (0.91-1.06) | 0.604 |
| 19p12 region | |||||||||||
| rs3795247* | 21906428 | T/C | 0.90 | 0.90 (0.82-0.98) | 0.021 | 0.80 (0.69-0.93) | 0.003 | 0.89 (0.82-0.97) | 0.007 | 0.83 (0.73-0.95) | 0.009 |
| rs79447188¶ | 22405414 | T/C | 0.03 | 1.20-(1.05-1.37) | 0.006 | 1.26 (1.03-1.55) | 0.024 | 1.13 (1.00-1.28) | 0.044 | 1.10 (0.90-1.34) | 0.342 |
| rs4330044¶ | 21905838 | T/C | 0.10 | 1.12 (1.02-1.22) | 0.021 | 1.25 (1.08-1.44) | 0.003 | 1.13 (1.03-1.23) | 0.007 | 1.20 (1.05-1.38) | 0.009 |
| rs35308521¶ | 21932095 | G/GA | 0.11 | 1.12 (1.02-1.23) | 0.015 | 1.24 (1.08-1.43) | 0.003 | 1.14 (1.05-1.25) | 0.002 | 1.21 (1.06-1.38) | 0.005 |
| rs12463030¶ | 21947607 | T/C | 0.95 | 0.88 (0.76-1.01) | 0.071 | 0.76 (0.60-0.95) | 0.016 | 0.85 (0.74-0.97) | 0.015 | 0.72 (0.58-0.89) | 0.002 |
| rs10421113# | 21929885 | T/C | 0.83 | 1.02 (0.95-1.10) | 0.575 | 1.11 (0.99-1.24) | 0.065 | 1.04 (0.98-1.11) | 0.227 | 1.11 (1.00-1.23) | 0.047 |
| rs10421342# | 21930003 | T/C | 0.83 | 1.02 (0.95-1.10) | 0.575 | 1.11 (0.99-1.24) | 0.065 | 1.04 (0.98-1.11) | 0.227 | 1.11 (1.00-1.23) | 0.047 |
§Effect allele frequency based on samples from the OncoArray study.
*Lead outcome variant in our original study [3].
¶Lead outcome variant with a survival phenotype in the new meta-analysis.
#Functional candidate variant.